CellMosaic is proud to introduce three new maleimide-activated protein carrier products for immunization and diagnostic applications. Designed for conjugation with cysteine (Cys) peptides, as well as small molecules and biopolymers containing free thiol groups, these products provide flexibility to meet diverse research needs.
Newly Released Products:
- Maleimide Activated BSA ML: 10-20 maleimide groups (2 mg & 6 mg)
- Maleimide Activated BSA LL: 2-8 maleimide groups (2 mg & 6 mg)
- Maleimide Activated KLH ML: 10-30 maleimide groups (2 mg & 6 mg)
Complete Product Line Overview:
| Product Name |
SKU |
Amount | Maleimide Loading |
| Maleimide Activated BSA HL |
CM52111-1x2MG |
2 mg |
20-30 |
|
CM52111-3x2MG |
6 mg |
||
| Maleimide Activated BSA ML |
CM52144-1x2MG |
2 mg | 10-20 |
|
CM52144-3x2MG |
6 mg | ||
| Maleimide Activated BSA LL |
CM52145-1x2MG |
2 mg | 2-8 |
|
CM52145-3x2MG |
6 mg | ||
| Maleimide Activated KLH HL |
CM52109-1x2MG |
2 mg | 40-80 |
|
CM52109-3x2MG |
6 mg | ||
| Maleimide Activated KLH ML |
CM52146-1x2MG |
2 mg | 10-30 |
|
CM52146-3x2MG |
6 mg | ||
| Bold cells indicate new products | |||
Key Features and Benefits:
- Wide Range of Loadings: Products offer maleimide group loadings from 2 to 80 groups per protein, enabling researchers to select the optimal conjugation level for their specific applications.
- Flexible Packaging: Available in 2 mg and 6 mg quantities to meet research and production needs.
- High-Quality Standards: Manufactured under strict quality control for consistent performance and reliability
--------------------------------------------
About CellMosaic, Inc.
CellMosaic is a Massachusetts-based biotech company specializing in the research and drug bioconjugate market. Bioconjugates are widely used as research tools, diagnostic reagents, and novel drug modalities, such as antibody-drug conjugates (ADCs), antibody-oligo conjugates (AOCs). Since its founding in 2008, CellMosaic® has invested significant research efforts in developing core technologies to address two major challenges in the field: advanced bioconjugation processes for producing high-quality bioconjugates and AqT® technologies for efficiently loading large amounts of hydrophobic small molecules onto biomolecules. Operating from its U.S. facility, CellMosaic® currently offers bioconjugation-related reagents and kits, customer bioconjugation services, contract bioconjugate development and manufacturing, and strategic partnerships for developing proprietary innovative AqT® ADC using its novel AqT® linker-modified drugs.